Monday , April 19 2021

The UK is recording another 315 deaths from Covid-19 and 6,385 cases while infections continue to decline



T

The UK recorded another 315 deaths related to Covid-19, bringing the total to 123,783.

The number is down 28 from Tuesday’s data and the lowest overall score on Wednesday, Oct. 28.

The latest figures released on Wednesday also show that a further 6,385 cases of coronavirus were reported during the last day. That’s roughly a third of the fewer than 9,938 cases recorded the same day last week. This leads to a total of 50,208 cases in the last seven days, more than 31% less than the week before.

There were 9,594 coronavirus patients at a hospital in England on Wednesday, March 3 at 8 a.m., the first time it had fallen below 10,000 since November 1, when there were 9,623.

Report

It is also a week-on-week decrease of 26% compared to 13,007 coronavirus patients hospitalized in England on 24 February and 72% from a peak of 34,336 coronavirus patients in England. ‘Hospitals January 18th.

Meanwhile, European countries today are urged to ‘continue’ to use the Oxford / AstraZeneca vaccine for the elderly to save lives, as new research has shown that a single dose provides outstanding protection.

Adam Finn, a professor of pediatrics at the University of Bristol, presented a new study in people over the age of 80 that found that an injection of Pfizer / BioNTech or Oxford prevented serious illnesses that could lead to hospitalization.

Calling on other countries to run out of stockpiles of Oxford stings, a member of the Joint Vaccination and Immunization Committee (JCVI) said at a briefing: .

“In the short term, the job is done in the UK.

“But in European countries there are many doses of AstraZenec vaccine, which are not given to people over the age of 65, in some cases in countries over the age of 55, due to a lack of data.

“Well, here’s the data. There are public health data from England and Scotland, and now we show that you can save the lives of the elderly by giving a dose of AstraZeneca.

“And these countries need to move on and start doing it as quickly as possible.”

The French government has said that people aged 65 to 74 with pre-existing conditions can now get the Oxford / AstraZeneca vaccine, after previously saying the lack of data means it should be limited to those under 65. Several EU countries still limit it to those under 65, including Germany.

A new study led by Professor Finn, which has not yet been reviewed, included elderly adults with pneumonia, Covid or other acute respiratory infections admitted to Bristol and Weston NHS Foundation Trust (UHBW) and North Bristol NHS Trust (NBT) universities. .

It included 466 adults over the age of 80, many of whom had other health problems, and about 90% of them were considered fragile.

The results showed that the dose of Pfizer was 79.3% effective 14 days after vaccination to prevent a disease severe enough to require hospitalization.

During the same period, a single dose of Oxford / AstraZeneca was 80.4% effective against the same level of disease in the same group, also from 14 days after vaccination.

Professor Finn said the study was conducted in a different way than the one published by PHE this week, but found very similar results.

The PHE study found that both injections reduced the risk of hospital treatment by more than 80% in those over 80 years of age.

“I think it gives confidence in the overall results,” Professor Finn said.

“I think their results confirm ours, and our results theirs.”

He said he expects the effectiveness to be even higher in the younger age groups and that protection in all groups will be maintained until people get a second dose.

Commenting on how vaccines seem to work better against serious diseases than against mild diseases, he added: “The general message is that all studies show that these two vaccines really do what we wanted them to do. And that is to prevent people from entering to the hospital and dying. “

Dr Catherine Hyams of the University of Bristol, who was working on a study to be published in The Lancet, said: ‘Despite the fragility and age of these patients, a dose of Pfizer or AstraZeneca is extremely effective in reducing hospital admissions and


Source link